Hepatocellular carcinoma (HCC) accounts for approximately 75%-85% of primary liver cancers and remains a top three cause of cancer-related mortality worldwide, with an estimated 900000 new cases and 830000 deaths annually. Despite advances demonstrated in recent phase III trials, median overall survival (OS) among patients with unresectable HCC treated with first-line immunotherapy and antiangiogenic combinations remains approximately 15-20 months, underscoring the biological aggressiveness of the disease. The molecular pathophysiology of HCC is shaped not only by recurrent genomic alterations including TP53, TERT promoter, CTNNB1, and chromatin-modifying genes but also by a chronically inflamed, fibrotic tumor microenvironment (TME) in which nuclear factor kappa-B, Janus kinase/signal transducer and activator of transcription, and transforming growth factor (TGF)-β signaling intersect with profound vascular remodeling. Aberrant angiogenesis represents a central hallmark of HCC. Immunohistochemical analyses demonstrate vascular endothelial growth factor (VEGF) positivity in approximately 65%-70% of tumors, with VEGF-expressing HCCs exhibiting significantly higher rates of capsular infiltration, microvascular invasion, intrahepatic metastasis, and inferior OS, with reported hazard ratios for death of approximately 1.5-2.0. In parallel, accumulation of hypoxia-inducible factor (HIF)-1α and HIF-2α in hypoxic tumors and following locoregional therapies (e.g., transarterial chemoembolization and radiofrequency ablation) transcriptionally activates VEGFA, ANGPT2, CXCL12, and glycolytic programs, driving neo-angiogenesis, vascular tortuosity, and metabolic reprogramming. Concurrent upregulation of MET, AXL, and fibroblast growth factor receptor signaling within tumor and stromal compartments further promotes invasion, epithelial-mesenchymal transition, and resistance to VEGF-targeted tyrosine kinase inhibitors. Non-parenchymal cells often constituting ≥ 50% of the tumor mass including liver sinusoidal endothelial cells, activated hepatic stellate cells, cancer-associated fibroblasts, and tumor-associated macrophages, secrete VEGF, ANGPT2, interleukin-6, CCL2, CXCL8, and TGF-β, reinforcing vascular abnormalization and T-cell exclusion. These molecular circuits are directly leveraged in contemporary clinical trials. In IMbrave150, atezolizumab plus bevacizumab achieved a median OS of 19.2 months vs 13.4 months with sorafenib (hazard ratio 0.66), with 12-month OS rates of approximately 67% vs 55% and objective response rates of 27% vs 12% by RECIST 1.1. In HIMALAYA, the STRIDE regimen (tremelimumab plus durvalumab) produced a median OS of 16.4 months compared with 13.8 months for sorafenib (hazard ratio 0.78), with 36-month OS rates near 30% vs 20%, respectively. Exploratory analyses from these and related studies indicate that angiogenic, hypoxia-related, interferon-γ, and WNT/β-catenin gene signatures stratify clinical benefit and illuminate mechanisms of primary resistance to immune–antiangiogenic therapy. This review integrates molecular, TME-level, and clinical trial data to define biomarker-aligned, mechanism-based vascular and immune targeting strategies aimed at achieving more durable disease control in advanced HCC.
Core Tip: Hepatocellular carcinoma (HCC) progression is governed by dynamic interactions between tumor genomics, stromal elements, hypoxia, and aberrant vascular signaling. The success of immune-antiangiogenic combinations validates the concept that vascular normalization and immune reprogramming are biologically interconnected processes. This review integrates molecular, tumor microenvironment-level, and clinical trial data to define biomarker-aligned, mechanism-based vascular and immune targeting strategies aimed at achieving more durable disease control in advanced HCC.